| アブストラクト | BACKGROUND: The potentially fatal attacks experienced by porphyria carriers are triggered by various porphyrinogenic drugs. However, determining the safety of particular drugs is challenging. METHODS: We retrospectively used the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) to identify drugs associated with porphyria as an adverse event (AE) extracted from data from January 2004 to March 2022. The associated search terms included "Porphyria," "Porphyria screen," "Porphyria non-acute," "Porphyria acute," "Acquired porphyria," and "Pseudoporphyria." Signal mining analysis was performed to identify the association between drugs and AEs by four algorithms, namely the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker. RESULTS: FAERS reported 1470 cases of porphyria-related AEs, and 406 drugs were screened after combining trade and generic names. All four algorithms identified 52 drugs with signals. The characteristics of all the reports and signaling drugs were analyzed. CONCLUSIONS: This is the first report of drug-associated porphyria that provides critical information on drug porphyrogenicity, facilitating rational and evidence-based drug prescription and improving the accuracy of porphyrogenicity prediction based on model algorithms. Moreover, this study serves a reference for clinicians to ensure that porphyrinogenic drugs are not prescribed to carriers of porphyria genetic mutations. |
|---|
| ジャーナル名 | Orphanet journal of rare diseases |
|---|
| 投稿日 | 2024/8/2 |
|---|
| 投稿者 | Wang, Qi; Zhuang, Jun Ling; Han, Bing; Chen, Miao; Zhao, Bin |
|---|
| 組織名 | Department of Hematology, Peking Union Medical College Hospital (PUMCH), Chinese;Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;chenm@pumch.cn.;Department of Pharmacy, Peking Union Medical College Hospital (PUMCH), Chinese;zhaobin@pumch.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39090656/ |
|---|
